AXTX delivers 2x daily leveraged exposure to AXTI (Accelerate Diagnostics), a microcap medical diagnostics company specializing in rapid antimicrobial susceptibility testing. This single-stock leveraged ETF amplifies both gains and losses for traders betting on AXTI's volatile price movements.
How It Works
The fund uses swap agreements and derivatives to achieve 200% of AXTI's daily performance, resetting exposure each trading day. Unlike diversified biotech ETFs, this concentrates all leverage on one $50M market cap company. Daily rebalancing means holding for multiple days creates path-dependent returns that diverge from 2x the stock's cumulative performance due to volatility decay.
Key Features
- Pure-play 2x leverage on a single microcap biotech stock with extreme volatility
- Zero expense ratio makes it cheaper than margin trading for intraday moves
- Provides leveraged exposure without options approval or margin requirements
Risks
- Daily reset means -20% stock move = -40% ETF loss; multi-day holds face severe compounding decay
- AXTI's microcap status means potential 50%+ daily swings could wipe out most capital overnight
- Counterparty risk from swaps plus liquidity risk as new fund with minimal assets
Who Should Own This
Day traders with high risk tolerance making directional bets on AXTI earnings, FDA announcements, or technical breakouts. Maximum holding period is 1-3 days due to volatility decay. This is a trading vehicle for those who understand leveraged ETF mechanics and can afford total loss — not suitable for any long-term portfolio allocation.